Transaction in Own Shares

Summary by AI ^BETAClose X

CVS Group plc has announced the purchase of 18,123 ordinary shares on December 18, 2025, as part of its share buyback program, with prices ranging from 1,248.00 pence to 1,268.00 pence per share, and a volume-weighted average price of 1,257.38 pence. These shares are intended for cancellation, which will reduce the total number of issued ordinary shares to 70,783,372, with no shares held in treasury. Since the program's inception, CVS has repurchased a total of 957,411 ordinary shares at a weighted average price of 1,217.39 pence.

Disclaimer*

CVS Group plc

19 December 2025

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 18 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase:	18/12/2025
Aggregate number of Ordinary Shares purchased:	18,123
Lowest price paid per share (GBp):	1,248.00
Highest price paid per share (GBp):	1,268.00
Volume weighted average price paid per share (GBp):	1,257.38

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,783,372 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,783,372 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 957,411 Ordinary Shares in aggregate at a weighted average price of 1,217.39 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
307	1250	18/12/2025 08:09:43	1353937584130558	XLON
102	1254	18/12/2025 08:37:43	1353937584133303	XLON
8	1254	18/12/2025 08:37:43	1353937584133304	XLON
453	1254	18/12/2025 08:37:43	1353937584133305	XLON
609	1262	18/12/2025 09:02:37	1353937584135463	XLON
255	1262	18/12/2025 09:02:37	1353937584135464	XLON
870	1264	18/12/2025 09:10:39	1353937584135960	XLON
228	1264	18/12/2025 09:16:40	1353937584136294	XLON
869	1262	18/12/2025 09:30:28	1353937584137015	XLON
760	1262	18/12/2025 09:30:28	1353937584137016	XLON
72	1258	18/12/2025 09:33:10	1353937584137105	XLON
174	1260	18/12/2025 09:57:19	1353937584138818	XLON
80	1258	18/12/2025 09:57:19	1353937584138822	XLON
70	1262	18/12/2025 10:14:15	1353937584139761	XLON
106	1260	18/12/2025 11:06:58	1353937584142803	XLON
81	1258	18/12/2025 11:38:14	1353937584143948	XLON
146	1258	18/12/2025 11:38:14	1353937584143951	XLON
105	1254	18/12/2025 11:45:05	1353937584144245	XLON
727	1252	18/12/2025 11:49:35	1353937584144455	XLON
328	1252	18/12/2025 11:49:39	1353937584144460	XLON
101	1252	18/12/2025 11:49:51	1353937584144475	XLON
774	1252	18/12/2025 11:49:54	1353937584144486	XLON
900	1250	18/12/2025 11:51:00	1353937584144598	XLON
908	1254	18/12/2025 11:59:04	1353937584144923	XLON
908	1254	18/12/2025 11:59:04	1353937584144932	XLON
901	1250	18/12/2025 12:00:26	1353937584145643	XLON
429	1250	18/12/2025 12:02:30	1353937584147471	XLON
376	1250	18/12/2025 12:02:30	1353937584147473	XLON
590	1250	18/12/2025 12:05:55	1353937584147883	XLON
622	1248	18/12/2025 12:07:00	1353937584148033	XLON
87	1248	18/12/2025 12:07:00	1353937584148034	XLON
300	1248	18/12/2025 12:13:16	1353937584149101	XLON
869	1258	18/12/2025 13:44:50	1353937584156800	XLON
376	1262	18/12/2025 14:29:32	1353937584160096	XLON
100	1260	18/12/2025 14:30:01	1353937584160298	XLON
793	1268	18/12/2025 14:55:35	1353937584164955	XLON
275	1268	18/12/2025 14:55:35	1353937584164956	XLON
275	1264	18/12/2025 15:07:55	1353937584166713	XLON
267	1264	18/12/2025 15:21:43	1353937584168395	XLON
100	1264	18/12/2025 15:21:43	1353937584168397	XLON
192	1264	18/12/2025 15:41:00	1353937584171506	XLON
144	1264	18/12/2025 15:41:00	1353937584171507	XLON
201	1264	18/12/2025 16:03:50	1353937584175041	XLON
198	1264	18/12/2025 16:03:54	1353937584175064	XLON
6	1268	18/12/2025 16:19:05	1353937584177834	XLON
258	1268	18/12/2025 16:22:43	1353937584178435	XLON
32	1268	18/12/2025 16:22:43	1353937584178436	XLON
25	1268	18/12/2025 16:22:43	1353937584178437	XLON
549	1268	18/12/2025 16:22:43	1353937584178438	XLON
217	1266	18/12/2025 16:23:21	1353937584178537	XLON

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR) cvsg@camarco.co.uk

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END